drugset / Trial / NCT07493577
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Phase 1/2
Not yet recruiting
82 enrolled
Dr David Hasan, M.D.
National Institute of Neurological Disorders and Stroke (NINDS) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Timeline
- Start
- 2026-07-23
- Primary completion
- 2029-01-23
- Completion
- 2032-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirofiban | Other / unclassified | 0.1 ug/kg | Intravenous |